This phase I/II study is trying to determine the best dose level, safety and tolerability of an oral targeted therapy (EO1001) in people with advanced EGFR, HER2 or HER4 positive cancerAn ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.

Exclusion

• Active infection requiring systemic treatment, defined as requiring antimicrobial, antifungal, or antiviral agents.
• Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
• Untreated or symptomatic brain metastases. Participants with treated or untreated brain metastases are NOT eligible if there has been a change in brain disease status in the 8 weeks prior to screening. This includes evidence of radiological progression, clinical decline and increasing steroid dose.
• Current or recent (within 10 days of Cycle 1 Day 1) use of full dose oral or parenteral anticoagulants or other thrombolytic agents for therapeutic (as opposed to prophylactic) purposes, clinically serious non-healing wounds, or incompletely healed bone fracture.
• Participants on > 2mg dexamethasone (or steroid equivalent).
• Ventriculoperitoneal (VP) shunts.
• Renal compromised or renal failure.
• Hepatic compromised or hepatic failure.
• Bullous and exfoliative skin disorders.
• Interstitial lung disease (ILD)
• Participants with adequate cardiac function ( less than or equal to NYHA class II) or normal cardiac function with left ventricular ejection fraction (LVEF) less than or equal to 50% at screening.
• Anticancer therapy within 4 weeks, or a minimum of 5 half-lives whichever is longer.
• Pregnancy or breast-feeding.
• Inability to swallow oral medications or having malabsorption syndrome.
• Unresolved adverse reactions to prior treatments NCI CTCAEv5 > Grade 1.
• Any serious medical or psychiatric conditions which the Investigator feels may interfere with the patient’s ability to give informed consent or participate in the procedures or evaluations of the study.
• Abnormal coagulation not corrected by plasma infusion (APTT > ULN or INR> 1.2).
• Participants of childbearing potential who do not agree to use at least 2 effective contraceptive methods throughout the study and for 6 months following completion of treatment.
• Female participants who are pregnant or lactating.
• Unstable angina or acute myocardial infarction less than or equal to 6 months prior to starting study treatment.
• Baseline QTc greater than or equal to 470 msec
• Cardiomyopathy.
• Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.